Top

Published in:

Open Access 01-12-2010 | Research article

Local erythropoietin and endothelial progenitor cells improve regional cardiac function in acute myocardial infarction

Authors: Andreas Stein, Martina Knödler, Markus Makowski, Sandra Kühnel, Stefan Nekolla, Alexandra Keithahn, Eliane Weidl, Philip Groha, Maren Schürmann, Atti Saraste, Rene Botnar, Robert AJ Oostendorp, Ilka Ott

Published in: BMC Cardiovascular Disorders | Issue 1/2010

Abstract

Background

Expanded endothelial progenitor cells (eEPC) improve global left ventricular function in experimental myocardial infarction (MI). Erythropoietin beta (EPO) applied together with eEPC may improve regional myocardial function even further by anti-apoptotic and cardioprotective effects. Aim of this study was to evaluate intramyocardial application of eEPCs and EPO as compared to eEPCs or EPO alone in experimental MI.

Methods and Results

In vitro experiments revealed that EPO dosed-dependently decreased eEPC and leukocyte apoptosis. Moreover, in the presence of EPO mRNA expression in eEPC of proangiogenic and proinflammatory mediators measured by TaqMan PCR was enhanced. Experimental MI was induced by ligation and reperfusion of the left anterior descending coronary artery of nude rats (n = 8-9). After myocardial transplantation of eEPC and EPO CD68+ leukocyte count and vessel density were enhanced in the border zone of the infarct area. Moreover, apoptosis of transplanted CD31 + TUNEL + eEPC was decreased as compared to transplantation of eEPCs alone. Regional wall motion of the left ventricle was measured using Magnetic Resonance Imaging. After injection of eEPC in the presence of EPO regional wall motion significantly improved as compared to injection of eEPCs or EPO alone.

Conclusion

Intramyocardial transplantation of eEPC in the presence of EPO during experimental MI improves regional wall motion. This was associated with an increased local inflammation, vasculogenesis and survival of the transplanted cells. Local application of EPO in addition to cell therapy may prove beneficial in myocardial remodeling.

Available only for authorised users

Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S, Lombardi M, Galiuto L, Liuzzo G, Andreotti F, et al: Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005, 26 (12): 1196-1204. 10.1093/eurheartj/ehi164.CrossRefPubMed

Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, et al: Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2005, 105 (1): 199-206. 10.1182/blood-2004-05-1831.CrossRefPubMed

Wojakowski W, Tendera M, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Ochala A, Ratajczak MZ: Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation. 2004, 110 (20): 3213-3220. 10.1161/01.CIR.0000147609.39780.02.CrossRefPubMed

Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003, 100 (8): 4802-4806. 10.1073/pnas.0630444100.CrossRefPubMedPubMedCentral

Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P: Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA. 2001, 98 (18): 10344-10349. 10.1073/pnas.181177898.CrossRefPubMedPubMedCentral

Ott I, Keller U, Knoedler M, Gotze KS, Doss K, Fischer P, Urlbauer K, Debus G, von Bubnoff N, Rudelius M, et al: Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction. Faseb J. 2005, 19 (8): 992-994.PubMed

Dawn B, Bolli R: Adult bone marrow-derived cells: regenerative potential, plasticity, and tissue commitment. Basic Res Cardiol. 2005, 100 (6): 494-503. 10.1007/s00395-005-0552-5.CrossRefPubMedPubMedCentral

Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B: Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007, 167 (10): 989-997. 10.1001/archinte.167.10.989.CrossRefPubMed

Belonje AM, Westenbrink BD, Voors AA, von Haehling S, Ponikowski P, Anker SD, van Veldhuisen DJ, Dickstein K: Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. Am Heart J. 2009, 157 (1): 91-96. 10.1016/j.ahj.2008.08.020.CrossRefPubMed

10.

van der Meer P, Lipsic E, Henning RH, de Boer RA, Suurmeijer AJ, van Veldhuisen DJ, van Gilst WH: Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail. 2004, 6 (7): 853-859.CrossRefPubMed

11.

Sterin-Borda L, Barcelo AC, Bozzini CE: Erythropoietin improves cardiac contractility in post-hypoxic mice. Br J Haematol. 2003, 121 (1): 180-186. 10.1046/j.1365-2141.2003.04239.x.CrossRefPubMed

12.

Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI: Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003, 100 (20): 11612-11617. 10.1073/pnas.1930406100.CrossRefPubMedPubMedCentral

13.

Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. Jama. 2005, 293 (1): 90-95. 10.1001/jama.293.1.90.CrossRefPubMedPubMedCentral

14.

Katavetin P, Inagi R, Miyata T, Shao J, Sassa R, Adler S, Eto N, Kato H, Fujita T, Nangaku M: Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem Biophys Res Commun. 2007, 359 (4): 928-934. 10.1016/j.bbrc.2007.05.207.CrossRefPubMed

15.

Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA. 1994, 91 (9): 3974-3978. 10.1073/pnas.91.9.3974.CrossRefPubMedPubMedCentral

16.

Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Tabira T, Sasaki R: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem. 1993, 268 (15): 11208-11216.PubMed

17.

Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML: Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999, 126 (16): 3597-3605.PubMed

18.

Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN: JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993, 74 (2): 227-236. 10.1016/0092-8674(93)90414-L.CrossRefPubMed

19.

Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A, Sawyer ST: Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood. 1999, 93 (11): 3757-3773.PubMed

20.

Ashley RA, Dubuque SH, Dvorak B, Woodward SS, Williams SK, Kling PJ: Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatr Res. 2002, 51 (4): 472-478. 10.1203/00006450-200204000-00012.CrossRefPubMed

21.

Carlini RG, Reyes AA, Rothstein M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995, 47 (3): 740-745. 10.1038/ki.1995.113.CrossRefPubMed

22.

Sayan H, Ozacmak VH, Guven A, Aktas RG, Ozacmak ID: Erythropoietin stimulates wound healing and angiogenesis in mice. J Invest Surg. 2006, 19 (3): 163-173. 10.1080/08941930600674694.CrossRefPubMed

23.

Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003, 102 (4): 1340-1346. 10.1182/blood-2003-01-0223.CrossRefPubMed

24.

Brunner S, Winogradow J, Huber BC, Zaruba MM, Fischer R, David R, Assmann G, Herbach N, Wanke R, Mueller-Hoecker J, et al: Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. Faseb J. 2009, 23 (2): 351-361. 10.1096/fj.08-109462.CrossRefPubMed

25.

Ott I, Neumann FJ, Schomig A: Neutrophil hyper-reactivity after exercise-induced angina pectoris. Coron Artery Dis. 1995, 6 (7): 525-532.PubMed

26.

Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H: Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res. 2006, 71 (4): 684-694. 10.1016/j.cardiores.2006.06.003.CrossRefPubMed

27.

Zohlnhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T, Meisetschlager G, von Wedel J, Bollwein H, Seyfarth M, et al: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. Jama. 2006, 295 (9): 1003-1010. 10.1001/jama.295.9.1003.CrossRefPubMed

28.

Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, et al: Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005, 149 (3): 408-413. 10.1016/j.ahj.2004.09.047.CrossRefPubMed

29.

Katz O, Gil L, Lifshitz L, Prutchi-Sagiv S, Gassmann M, Mittelman M, Neumann D: Erythropoietin enhances immune responses in mice. Eur J Immunol. 2007, 37 (6): 1584-1593. 10.1002/eji.200637025.CrossRefPubMed

30.

Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, Neumann D: Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. Mol Immunol. 2009, 46 (4): 713-721. 10.1016/j.molimm.2008.10.004.CrossRefPubMed

31.

Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA. 2001, 98 (9): 5181-5186. 10.1073/pnas.081275298.CrossRefPubMedPubMedCentral

32.

Prutchi Sagiv S, Lifshitz L, Orkin R, Mittelman M, Neumann D: Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?. Exp Hematol. 2008, 36 (12): 1682-1690. 10.1016/j.exphem.2008.07.010.CrossRefPubMed

33.

Furlani D, Klopsch C, Gabel R, Ugurlucan M, Pittermann E, Klee D, Wagner K, Li W, Wang W, Ong LL, et al: Intracardiac erythropoietin injection reveals antiinflammatory potential and improved cardiac functions detected by Forced Swim Test. Transplant Proc. 2008, 40 (4): 962-966. 10.1016/j.transproceed.2008.03.033.CrossRefPubMed

34.

Gaebel R, Klopsch C, Furlani D, Yerebakan C, Li W, Ugurlucan M, Ma N, Steinhoff G: Single high-dose intramyocardial administration of erythropoietin promotes early intracardiac proliferation, proves safety and restores cardiac performance after myocardial infarction in rats. Interact Cardiovasc Thorac Surg. 2009, 9 (1): 20-5. 10.1510/icvts.2008.191916.CrossRef

35.

Klopsch C, Furlani D, Gabel R, Li W, Pittermann E, Ugurlucan M, Kundt G, Zingler C, Titze U, Wang W, et al: Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. J Cell Mol Med. 2009, 13 (4): 664-679. 10.1111/j.1582-4934.2008.00546.x.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/10/43/prepub

Title: Local erythropoietin and endothelial progenitor cells improve regional cardiac function in acute myocardial infarction
Authors: Andreas Stein
Martina Knödler
Markus Makowski
Sandra Kühnel
Stefan Nekolla
Alexandra Keithahn
Eliane Weidl
Philip Groha
Maren Schürmann
Atti Saraste
Rene Botnar
Robert AJ Oostendorp
Ilka Ott
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2010
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/1471-2261-10-43

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Local erythropoietin and endothelial progenitor cells improve regional cardiac function in acute myocardial infarction

Abstract

Background

Methods and Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods and Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Difference in the topography of atherosclerosis in the left versus right coronary artery in patients referred for coronary angiography

A mobile phone-based care model for outpatient cardiac rehabilitation: the care assessment platform (CAP)

Distribution, size, shape, growth potential and extent of abdominal aortic calcified deposits predict mortality in postmenopausal women

Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials

Outcome and quality of life after aorto-bifemoral bypass surgery

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page